Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL-Reference-Cited by-同舟云学术

Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL

Published:2021-02-21 Issue:7 Volume:62 Page:1674-1681
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jindal Nishant¹,Lad Deepesh P.¹^ORCID,Malhotra Pankaj¹,Prakash Gaurav¹,Khadwal Alka¹,Jain Arihant¹,Sachdeva Manupdesh Singh²,Sreedharanunni Sreejesh²,Naseem Shano²,Varma Neelam²,Varma Subhash¹

Affiliation:

1. Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

2. Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Funder

Postgraduate Institute of Medical Education and Research intramural

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1885668

Reference15 articles.

1. Global Health Data Exchange: GBD results tool. [cited 2020 Oct 1]. Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2017-permalink/7370f9af81d6bc6eb855f6f4b122eacf.

2. Reduced Dose Ibrutinib Due to Financial Toxicity in CLL

3. Remission maintenance treatment options in chronic lymphocytic leukemia

4. Lenalidomide for the Treatment of B-Cell Malignancies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10

2. How Do We Manage Chronic Lymphocytic Leukemia in India;Current Hematologic Malignancy Reports;2024-02-01

3. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis;The Lancet Haematology;2022-12

4. Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-09-14

5. Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis;Current Oncology;2022-06-14